Radiofrequency Ablation of Papillary Thyroid Microcarcinoma

Status Active, not recruiting

Clinical Trial Summary

Traditionally, surgery has been the standard recommendation for treating papillary thyroid cancer. The risk of surgery including permanent hoarseness, permanent hypocalcemia, a mid-cervical scar, and the potential for permanent hypothyroidism may be unacceptable for some patients, especially with low risk papillary thyroid carcinoma. The recent American Thyroid Association guidelines have proposed the option of active surveillance with low risk papillary thyroid cancer less than 210 mm. However, most patients find observation anxiety provoking knowing of having cancer. Radiofrequency ablation (RFA) of small low risk papillary thyroid cancer is a promising therapeutic modality for these patients that reduces the risks associated with surgery and the anxiety of taking a watchful approach. However, this technique has not been validated in the North American population. The investigators aim to describe the investigators' initial experience with RFA of low risk papillary thyroid microcarcinoma (PTMC) compared to active surveillance (AS) done by Head and Neck Endocrine surgeons at Johns Hopkins Medical Institute. Primary objective: - To evaluate the safety, efficacy and oncological outcomes of the procedure. Secondary objective: - To determine the patient functional outcomes in comparison to the observational control.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05132205
Study type	Interventional
Source	Johns Hopkins University
Contact
Status	Active, not recruiting
Phase	N/A
Start date	December 17, 2021
Completion date	September 28, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01441154` - Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment
Active, not recruiting	`NCT04544111` - PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer	Phase 2
Recruiting	`NCT03469011` - A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.	Phase 1
Recruiting	`NCT05752669` - Oxidative Stress and Mitochondrial TERT in Papillary Thyroid Cancer.
Recruiting	`NCT04076514` - The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma
Active, not recruiting	`NCT01723202` - Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer	Phase 2
Recruiting	`NCT05500508` - Oral AMXT 1501 Dicaprate in Combination With IV DFMO	Phase 1/Phase 2
Active, not recruiting	`NCT02568267` - Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)	Phase 2
Unknown status	`NCT02140476` - Comparative Analysis Between Bipolar Device and Conventional Tie & Suture Technique in Thyroidectomy	N/A
Recruiting	`NCT06286631` - Prediction of Lymph Node Metastasis in Patients With Thyroid Malignancy by a New Scale
Completed	`NCT06325787` - Image-guided Thermal Ablation vs. Lobectomy for Solitary Papillary Thyroid Microcarcinoma	N/A
Terminated	`NCT01974284` - Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma	N/A
Active, not recruiting	`NCT00984191` - Pilot 99mTechnetium-MIBI Single Photon Emission Computed Tomography - Computed Tomography (SPECT-CT) in Papillary Carcinoma (CA) Thyroid	N/A
Active, not recruiting	`NCT04731467` - A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT05668962` - Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC	Phase 2
Completed	`NCT02178345` - Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer
Completed	`NCT03470259` - Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging	Phase 1
Active, not recruiting	`NCT04129411` - Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation	N/A
Recruiting	`NCT03899792` - A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors	Phase 1/Phase 2
Completed	`NCT05873283` - Papillary Thyroid Cancer and Central Lymp Node Dissection